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Abstract
Inactivation of the gene encoding the adenomatous polyposis coli (APC) tumour suppressor protein is recognized
as the key early event in the development of colorectal cancers (CRC). Apc loss leads to nuclear localization of
beta-catenin and constitutive activity of the beta-catenin-Tcf4 transcription complex. This complex drives the
expression of genes involved in cell cycle progression such as c-Myc and cyclin D2. Acute loss of Apc in the small
intestine leads to hyperproliferation within the intestinal crypt, increased levels of apoptosis, and perturbed
differentiation and migration. It has been demonstrated that c-Myc is a critical mediator of the phenotypic
abnormalities that follow Apc loss in the intestine. As it may be difficult to pharmacologically inhibit transcription
factors such as c-Myc, investigating more druggable targets of the Wnt-c-Myc pathway within the intestine may
reveal potential therapeutic targets for CRC. Recent work in our laboratory has shown that the cyclin D2-cyclin-
dependent kinase 4/6 (CDK4/6) complex promotes hyperproliferation in Apc deficient intestinal tissue and Apc
Min/+
adenomas. We showed that the hyperproliferative phenotype associated with Apc loss in vivo was partially
dependent on the expression of cyclin D2. Most importantly, tumour growth and development in Apc
Min/+ mice
was strongly perturbed in mice lacking cyclin D2. Furthermore, pharmacological inhibition of CDK4/6 suppressed
the proliferation of adenomatous cells. This commentary discusses the significance of this work in providing
evidence for the importance of the cyclin D2-CDK4/6 complex in colorectal adenoma formation. It also argues that
inhibition of this complex may be an effective chemopreventative strategy in CRC.
Introduction
Unscheduled cell division is characteristic of cancer cells
[1]. As such, normal cell division is a tightly controlled
process that only permits cells to divide in a timely and
restricted manner. This process is directed by two
classes of proteins, a group of serine/threonine kinases
termed cyclin-dependent kinases (CDKs) and their acti-
vating binding partners, cyclins [2].
Heterodimeric complexes of CDKs and cyclins drive
all stages of the cell cycle. The G1/S phases of the cell
cycle are primarily directed by the sequential phosphor-
ylation of the retinoblastoma susceptibility protein Rb.
Hypophosphorylated Rb binds to E2F and functions as a
transcriptional repressor of E2F target genes. In early
G1 phase, CDK4 and CDK6 are activated by D-type
cyclins leading to phosphorylation of Rb. This leads to
partial dissociation of the E2F/Rb complex and expres-
sion of E2F target genes required for cell cycle progres-
sion such as cyclins A and E. The accumulation of cyclin
E leads to activation of CDK2 and further phosphoryla-
tion of Rb. This leads to full release of E2F, further acti-
vation of E2F targets and entry into S phase [3,4]. During
S phase a complex of cyclin A-CDK2 drives S phase pro-
gression by phosphorylation of various proteins involved
in DNA replication [5]. As S phase concludes, the activity
of cyclin A-CDK1 initiates prophase and finally, the
cyclin B-CDK1 complex contributes to completion of
mitosis [6,7]. Cell cycle progression is also controlled by
inhibition of cdk activity by two families of inhibitors.
Cyclin D-CDK4/6 complexes are inhibited by the INK4
family (p15
INK4b,p 1 6
INK4a,p 1 8
INK4c and p19
INK4d)a n d
cyclin A/B/E-CDK1/2 complexes by the Cip/Kip family
(p21
Cip1/Waf1/Sdi1, p27
Kip1 and p57
Kip2) [8]. * Correspondence: o.sansom@beatson.gla.ac.uk
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of tumourigenesis, it would be predicted that inap-
propriate activation of CDK/cyclin complexes would
occur in cancer. This has proven to be the case, with
deregulation of CDK4 and CDK6 implicated in a wide
variety of tumours [9]. A common mechanism by which
this occurs is inactivation of p16
INK4a by gene deletion,
point mutation or promoter methylation. Alternatively,
CDK4 and/or CDK6 activity can be increased and this is
observed in several tumour types including glioma,
breast tumours, lymphoma and melanoma [9]. Cyclin
D1 is the most commonly over expressed D-type cyclin
in human tumours. Its deregulated expression is
o b s e r v e di naw i d ev a r i e t yof tumour types including
non-small cell lung cancer and carcinomas of breast,
head and neck and oesophagus [10]. Additionally, cyclin
D2 is commonly over expressed in colon tumours and
its over expression may be related to a higher tumour-
node-metastasis (TNM) stage of tumour [11]. E-type
cyclins are also frequently over expressed, and their
inhibitors p21
Cip1/Waf1/Sdi1 and p27
Kip1 often silenced, in
human tumours suggesting that CDK2 activity may be
dysregulated in human cancer [12].
Discussion
In a recent study from our laboratory we set out to test
the requirement for the cyclin D2-CDK4/6 complex in
driving cell cycle progression following activation of
Wnt signalling due to Apc loss [13]. Previous work from
our laboratory has demonstrated that loss of Apc in the
mouse intestine leads to enhanced Wnt signalling which
drives activation of c-Myc [14]. We have also shown
that c-Myc is required for Wnt driven intestinal prolif-
eration [15]. As it has been demonstrated that the cyclin
D-CDK4/6 complex is an important downstream media-
tor of c-Myc signalling we reasoned that cyclin D2 may
be required downstream of c-Myc for proliferation fol-
lowing loss of Apc [16,17]. We initially demonstrated
that expression of both cyclin D2 and CDK4 are upre-
gulated following Apc loss in the intestinal epithelium.
Moreover, we showed that expression of this complex
requires c-Myc and correlates with phosphorylation of
Rb, indicating that these over expressed proteins form a
functionally active complex.
To test whether cyclin D2 is required for hyperproli-
feration following acute Wnt activation we crossed
cyclin D2 deficient mice to ones carrying inducible
floxed alleles of Apc. Interestingly, when we specifically
deleted Apc in the small intestine of these mice we
observed a significant reduction in proliferation of Apc/
cyclin D2 double deficient intestines compared to the
intestines of Apc deficient mice. This is in contrast to
normal enterocyte intestinal proliferation within the
cyclin D2 deficient mice. This indicates that efficient
proliferation in cells where Wnt signalling is deregulated
requires high levels of cyclin D2, whereas normal prolif-
eration is not cyclin D2 dependent.
Apc
Min/+ mice are heterozygous for a truncating muta-
tion at codon 850 of Apc. Spontaneous loss of the wild-
type copy of Apc leads to initiation of multiple intestinal
adenomas that model early stages of CRC. Similar to
acute Apc loss, the ademonas that arise in this model
show elevated Wnt signalling and their proliferation is
dependant upon over expression of c-Myc [18]. We
investigated the effect of cyclin D2 loss in this model
and observed a slowing of tumourigenesis and reduced
proliferation in the intestinal tumours of mice lacking
cyclin D2. This further demonstrates a requirement for
cyclin D2 in Wnt driven hyperproliferation. Although
not immediately expressed following Apc loss, cyclin D1
accumulates in the nuclei of Apc deficient tumour cells
[19,20]. To test if cyclin D1 could be partially compen-
sating for the loss of cyclin D2 in Apc deficient cells we
combined cyclin D2 loss with cyclin D1 heterozygosity
in Apc
Min/+ mice. We found that this had an additive
effect on suppression of tumourigenesis with very low
numbers of tumours developing in the double deficient
mice. Furthermore, the tumours that did arise had very
low numbers of proliferative cells. This raises the
tempting possibility that inhibition of cyclin D-CDK4/6
complexes may prevent proliferation of Apc deficient
cells.
To test this hypothesis and to confirm that the effects
on proliferation mediated by cyclin deficiency were due
to interactions with CDK4/6, we treated Apc
Min/+ mice
that had developed tumours with a novel small-molecule
pharmacologic inhibitor of CDK4/6, PD0332991. This
molecule has been shown to selectively inhibit CDK4/6
in vivo and can initiate regression in colo-205 colon car-
cinoma xenografts [21,22]. Following treatment with this
inhibitor for 5 days, tumours showed reduced prolifera-
tion levels, whereas normal tissue was proliferating nor-
mally. This data provides additional evidence that Apc
deficient tissue is particularly dependant on high levels
of cyclin D2-CDK4/6 activity for proliferation.
Animal knockout models of cyclin D-CDK family
members have indicated a large amount of functional
redundancy between members of different complexes
[12]. This raises the possibility that specific inhibition of
particular CDKs may not be successful or may lead to
development of resistance. In our study, we demon-
strated that short term treatment with PD0332991 is
capable of illicting a cellular response similar to that of
genetic deletion of cyclin D2. How this translates over
the longer term in this model remains to be seen, and it
is possible that over time other CDKs may compensate
for inhibition of CDK4/6. Encouragingly, rechallenge
experiments performed with Colo-205 colon xenografts
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ment with PD0332991 [22]. Thus, it may be the case
that Apc deficient intestinal cells are exquisitely sensitive
to CDK4/6 inhibition and there is no immediate redun-
dancy between CDKs. The study we carried out focused
on the initial stages of colorectal adenoma formation. A
number of murine models that mimic later stages of
CRC have recently been developed [23,24]. A focus of
future research should be to d e t e r m i n et h ee f f i c a c yo f
PD0332991 and similar compounds in suppressing
tumour growth in models such as these. This will give
us a better understanding of the roles of cyclin/CDK
complexes in later stage disease and determine if their
inhibition may be a viable strategy in the treatment of
CRC.
Conclusions
In conclusion, our study has provided important in vivo
evidence of an essential role for the cyclin D2-CDK4/6
complex in efficient hyperproliferation in tumour cells
where Wnt is activated (Figure 1). We would therefore
argue that the use of CDK4/6 inhibitors such as
PD0332991 warrants further investigation in murine
models of CRC.
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Figure 1 Cyclin D2-CDK4/6 complex drives efficient hyperproliferation in Apc deficient cells. (A) In the normal intestinal epithelium Wnt
activity and hence c-Myc levels are restricted. This prevents accumulation of the cyclin D2-CDK4/6 complex and suppresses proliferation. (B) In
Apc deficient cells Wnt activity and c-Myc levels are high. The high levels of c-Myc lead to accumulation of cyclin D2 and CDK4/6, possibly via
their direct transcriptional activation. The complex of cyclin D2 and CDK4/6 phosphorylates Rb and permits E2F to drive cell cycle entry and
subsequent hyperproliferation.
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